PINE BROOK, N.J. -- Elusys Therapeutics, Inc., a biotechnology Â company developing targeted anti-infective antibodies to fight life-threatening infections, announces that it has entered into an exclusive Â collaborative research and license agreement with Pfizer Inc. to develop new Â therapeutics for select infectious diseases using Elusys' HP Antibody technology.Â The research collaboration will includeÂ ETI-211, an HP Antibody for the treatment of methicillin-resistant Staphylococcus aureus (MRSA)Â infections, in addition to research into other indications.Â
Under the terms of the agreement, Elusys and Pfizer will collaborate on Â determining the full product profile of ETI-211 and perform research on other Â indications of the HP Antibody technology.Â Elusys will receive an upfront Â equity investment, research and development funding plus near-term Â research milestones.Â Elusys has also granted Pfizer an option to acquire an Â exclusive worldwide license to products developed under the agreement, and Â upon exercise, the company will receive significant clinical and sales
milestones, as well as royalties on future sales of products resulting from theÂ collaboration.
HP Antibodies represent a unique approach to the treatment of a variety of Â infectious diseases by enhancing the effectiveness of the body's naturalÂ defense mechanisms to remove and destroy life-threatening pathogens.Â An Â HP Antibody drug consists of a monoclonal antibody specific to an immune Â receptor (CR1) that is chemically linked to a second antibody that binds a Â particular pathogen.Â By targeting CR1, HP Antibodies enhance a natural Â clearance mechanism and direct the rapid removal of pathogens into liver Â macrophages, where they are destroyed and removed from the body.
Elizabeth Posillico, PhD, president and CEO of Elusys Therapeutics Â commented, "We are delighted that Pfizer has recognized the potential value Â of our HP Antibody technology as a novel approach for the treatment of life-threatening infections.Â Pfizer's impressive scientific team and expertise in Â infectious diseases provides Elusys with a strong partner to advance HP Antibody products into human clinical trials."Â Posillico added, "In parallel with the collaborative research on ETI-211, Elusys will continue to advance its other internal clinical development programs.Â These include Anthim, our Phase I therapeutic for anthrax infection and our HIV HP Antibody and CR1 Vaccine programs."
Source: Elusys Therapeutics Inc.